Effect of salivary gland adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of macrophage activating factor
- PMID: 14767536
Effect of salivary gland adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of macrophage activating factor
Abstract
The aim of this study was to clarify the effects of alpha-N-acetylgalactosaminidase (alpha-NaGalase) produced by human salivary gland adenocarcinoma (SGA) cells on the bioactivity of macrophage-activating factor (GcMAF). High exo-alpha-NaGalase activity was detected in the SGA cell line HSG. HSG alpha-NaGalase had both exo- and endo-enzyme activities, cleaving the Gal-GalNAc and GalNAc residues linked to Thr/Ser but not releasing the [NeuAc2-6]GalNac residue. Furthermore, GcMAF enzymatically prepared from the Gc protein enhanced the superoxide-generation capacity and phagocytic activity of monocytes/macrophages. However, GcMAF treated with purified alpha-NaGalase did not exhibit these effects. Thus, HSG possesses the capacity to produce larger quantities of alpha-NaGalase, which inactivates GcMAF produced from Gc protein, resulting in reduced phagocytic activity and superoxide-generation capacity of monocytes/macrophages. The present data strongly suggest that HSG alpha-NaGalase acts as an immunodeficiency factor in cancer patients.
Similar articles
-
Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.Comp Biochem Physiol A Mol Integr Physiol. 2002 May;132(1):1-8. doi: 10.1016/s1095-6433(01)00522-0. Comp Biochem Physiol A Mol Integr Physiol. 2002. PMID: 12062184
-
Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).Int J Cancer. 2008 Jan 15;122(2):461-7. doi: 10.1002/ijc.23107. Int J Cancer. 2008. Retraction in: Int J Cancer. 2014 Sep 15;135(6):1509. PMID: 17935130 Retracted.
-
Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.Cancer Res. 1997 Jun 1;57(11):2187-92. Cancer Res. 1997. PMID: 9187119 Clinical Trial.
-
Is α-N-acetylgalactosaminidase the key to curing cancer? A mini-review and hypothesis.J BUON. 2017 Nov-Dec;22(6):1372-1377. J BUON. 2017. PMID: 29332325 Review.
-
Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto.Cancer Treat Res Commun. 2022;31:100537. doi: 10.1016/j.ctarc.2022.100537. Epub 2022 Feb 18. Cancer Treat Res Commun. 2022. PMID: 35217488 Review.
Cited by
-
The Effect of Fucoidan from the Brown Alga Fucus evanescence on the Activity of α-N-Acetylgalactosaminidase of Human Colon Carcinoma Cells.Mar Drugs. 2018 May 10;16(5):155. doi: 10.3390/md16050155. Mar Drugs. 2018. PMID: 29748462 Free PMC article.
-
Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.Molecules. 2023 Feb 6;28(4):1570. doi: 10.3390/molecules28041570. Molecules. 2023. PMID: 36838558 Free PMC article.
-
shRNA-mediated downregulation of α-N-Acetylgalactosaminidase inhibits migration and invasion of cancer cell lines.Iran J Basic Med Sci. 2017 Sep;20(9):1021-1028. doi: 10.22038/IJBMS.2017.9271. Iran J Basic Med Sci. 2017. PMID: 29085597 Free PMC article.
-
Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside.Caspian J Intern Med. 2017 Fall;8(4):228-238. doi: 10.22088/cjim.8.4.228. Caspian J Intern Med. 2017. PMID: 29201312 Free PMC article. Review.
-
Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen.Appl Radiat Isot. 2008 Mar;66(3):278-87. doi: 10.1016/j.apradiso.2007.07.029. Epub 2007 Aug 17. Appl Radiat Isot. 2008. PMID: 17890096 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous